Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 135

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1A
Chunk 135
---
 fees if we are found to have willfully infringed a
patent. A finding of infringement could prevent us from commercializing product candidates or force us to cease some of our business operations,
which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties
could have a similar negative impact on our business.

If we are unable to protect the confidentiality
of our trade secrets, our business and competitive position would be harmed. 

If we are able to raise sufficient capital and potentially
license or acquire new technologies, then in addition to seeking patents for the new technologies and product candidates, we also plan
to rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position.
Any non-disclosure agreements (“NDAs”) or similar agreements entered into by the Company may not be with all relevant parties,
or adequately protect the confidentiality of our trade secrets. Moreover, to the extent we enter into such agreements, any of these parties
may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate
remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive
and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or
unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor,
we would have no right to prevent them from sharing such trade secrets or from using that technology or information to compete with us.
If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.

 20 

Risks Related
to Our Employee Matters, Managing Growth and Macroeconomic Conditions 

If we successfully identify new product candidates
and license those rights, then our future success will also depend on our ability to attract, hire, retain and motivate executives, key
employees, and our general workforce. 

If we are able to raise sufficient capital and potentially
license or acquire new technologies, then we will be highly dependent on the product development, clinical and business development expertise
of the principal members of our management, scientific and clinical teams. If we are unable to raise more capital in the near term, we
may be required to cease our operations altogether.

Moreover, our business plan relies significantly on
the continued services of